Piper Sandler maintains Guardant Health at Overweight, lowers price target to $190 from $193

Piper Sandler kept its Overweight rating on Guardant Health but reduced its price target to $190 from $193, suggesting a 19.7% upside from the Nov 9 close of $158.79. Recent analyst notes have price targets ranging from $200 to $210.

Original reporting
Published Nov 10, 2026, 12:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 12:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Piper Sandler maintains Guardant Health at Overweight, lowers price target to $190 from $193 — source image
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The analyst downgrade reflects a slight shift in valuation but does not indicate a major change in fundamentals.

02

Market read

Small but actionable for traders monitoring analyst updates on biotech stocks.

03

What to watch

Recent trial data and partnership announcements could offset the modest target reduction.

Relevance 6/10Novelty 5/10Timing: today

Background

Guardant Health is a liquid biopsy company whose stock is closely watched after recent trial results.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Piper Sandler lowered Guardant Health's price target to $190 from $193.

Expected impact

likely slight downward pressure as the market prices in the lower target

Evidence & confidence

A 1.6% target reduction is modest but may prompt short‑term sellers.

Market effects

Minor impact on liquid biopsy/diagnostics sector as analysts adjust expectations.

Limited to US biotech investors.

Low global relevance.

Counterpoint

Target cut may be overly cautious; upside potential remains if upcoming data beats expectations.

Key entities

  • Piper Sandler

    Equity research firm that issued the target cut.

  • Guardant Health

    US‑listed liquid biopsy firm (ticker GH).

Related articles

$GHHighAI 8/10

Why is Guardant Health stock climbing today?

Guardant Health (GH) stock rose 2.5% in pre-market trading after pricing a $500M offering of 0% convertible notes due 2032, with a 35% premium conversion price. The company plans to use proceeds to repurchase $395.2M of existing convertible notes due 2027, optimizing its balance sheet. The move came amid broader market headwinds for growth and tech names.